The Zhitong Finance App learned that New Lotus (02206) was listed for the first time. According to the announcement, each share was priced at HK$40.2. A total of 6,517,300 shares were issued, 50 shares per lot, with a net proceeds of about HK$229 million. As of press release, it rose 27.61% to HK$51.3, with a turnover of HK$96.574 million.

According to the prospectus, New Lotus is a major supplier of traditional Chinese medicine (TCM) tablet products in China. According to Frost & Sullivan's data, based on revenue from Chinese herbal medicine products in 2025, New Lotus ranked 2nd in China, accounting for 0.4% of the market share in a highly competitive market pattern, while the top five market participants together held 2.7% of the market share.

The Group serves a wide range of institutional and retail customers — including hospitals and medical institutions, medical trading companies, pharmacies, pharmaceutical companies and, more recently, individual consumers — providing traditional herbal preparations, health products and health management services. The Group operates in most provinces in mainland China, as well as Hong Kong, Taiwan and selected overseas markets such as Vietnam and Malaysia.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.